Hepatitis B and C

Research output: Contribution to journalReview article

Abstract

Chronic viral hepatitis is a global health threat and financial burden. Hepatitis B and C viruses (HBV and HCV) are the most common causes of chronic viral hepatitis in the United States. Most cases are asymptomatic before adulthood. Research has resulted in effective therapy for HCV and the promise of effective therapies for HBV. For HCV, therapy is pegylated interferon and ribavirin. Clinical trials with effective direct-acting antiviral agents are underway in pediatrics. For HBV, approved agents are alpha-interferon, lamivudine, adefovir, tenofovir, and entecavir. However, treatment seldom results in functional cure and more effective therapies are urgently needed.

Original languageEnglish (US)
Pages (from-to)641-658
Number of pages18
JournalPediatric Clinics of North America
Volume64
Issue number3
DOIs
StatePublished - Jun 1 2017

Keywords

  • Direct-acting antiviral agents
  • Hepatitis B
  • Hepatitis C
  • Pegylated interferon
  • Spontaneous viral clearance
  • Sustained virologic response

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Medicine(all)

Fingerprint Dive into the research topics of 'Hepatitis B and C'. Together they form a unique fingerprint.

  • Cite this